[60] Kannagi M*, Hasegawa A, Nagano Y, Iino T, Okamura J, Suehiro Y. Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: a hope for disease-preventive therapy. Cancer Sci. 2019, in press.

[59] Sawada L, Nagano Y, Hasegawa A, Kanai H, Nogami K, Ito S, Sato T, Yamano Y, Tanaka Y, Masuda T, Kannagi M*. IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 13(9):e1006597, 2017

[58] Murakami Y, Hasegawa A*, Ando S, Tanaka R, Masuda T, Tanaka Y, Kannagi M. A novel mother-to-child human T-cell leukaemia virus type 1 (HTLV-1) transmission model for investigating the role of maternal anti-HTLV-1 antibodies using orally infected mother rats. J Gen Virol. 98(4):835-846, 2017

[57] Ando S, Hasegawa A*, Murakami Y, Zeng N, Takatsuka N, Maeda Y, Masuda T, Suehiro Y, Kannagi M. HTLV-1 Tax-Specific CTL Epitope-Pulsed Dendritic Cell Therapy Reduces Proviral Load in Infected Rats with Immune Tolerance against Tax. J Immunol. 198(3):1210-1219, 2017


[56] Takahata T, Takeda E, Tobiume M, Tokunaga K, Yokoyama M, Huang YL, Hasegawa A, Shioda T, Sato H, Kannagi M, Masuda T*. Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase. J Virol. 91(1) pii: e02003-16, 2016


[55] Masuda T*, Sato Y, Huang YL, Koi S, Takahata T, Hasegawa A, Kawai G, Kannagi M. Fate of HIV-1 cDNA intermediates during reverse transcription is dictated by transcription initiation site of virus genomic RNA. Sci Rep. 5:17680, 2015

[54] Suehiro Y, Hasegawa A, Iino T, Sasada A, Watanabe N, Matsuoka M, Takamori A, Tanosaki R, Utsunomiya A, Choi I, Fukuda T, Miura O, Takaishi S, Teshima T, Akashi K, Kannagi M*, Uike N, Okamura J. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 169(3):356-67, 2015

[53] Kinpara S, Ito S, Takahata T, Saitoh Y, Hasegawa A, Kijiyama M, Utsunomiya A, Masuda M, Miyazaki Y, Matsuoka M, Nakamura M, Yamaoka S, Masuda T, Kannagi M*. Involvement of double-stranded RNA-dependent protein kinase and antisense viral RNA in the constitutive NFκB activation in adult T-cell leukemia/lymphoma cells. Leukemia. 29(6):1425-9, 2015


[52] Araya N, Sato T, Ando H, Tomaru U, Yoshida M, Coler-Reilly A, Yagishita N, Yamauchi J, Hasegawa A, Kannagi M, Hasegawa Y, Takahashi K, Kunitomo Y, Tanaka Y, Nakajima T, Nishioka K, Utsunomiya A, Jacobson S, Yamano Y. HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells. J Clin Invest. 124(8):3431-42, 2014

[51] Tanaka Y, Takahashi Y, Tanaka R, Kodama A, Fujii H, Hasegawa A, Kannagi M, Ansari AA, Saito M. Elimination of human T cell leukemia virus type-1-infected cells by neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies against human t cell leukemia virus type-1 envelope gp46. AIDS Res Hum Retroviruses. 30(6):542-52, 2014


[50] S. Kinpara, M. Kijiyama, A. Takamori, A. Hasegawa, A. Sasada, T. Masuda, Y. Tanaka, A. Utsunomiya and M. Kannagi*. Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology. 10: 52, 2013.

[49] Tamai, Y., A. Hasegawa*, A. Takamori, A. Sasada, R. Tanosaki, I. Choi, A. Utsunomiya, Y. Maeda, Y. Yamano, T. Eto, K. R. Koh, H. Nakamae, Y. Suehiro, K. Kato, S. Takemoto, J. Okamura, N. Uike, and M. Kannagi. Potential Contribution of a Novel Tax Epitope-Specific CD4+ T Cells to Graft-versus-Tax Effect in Adult T Cell Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation. J Immunol. 190(8): 4382-92. 2013 （学位論文)


[48] Kannagi, M*, A. Hasegawa, A. Takamori, S. Kinpara, and A. Utsunomiya. The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases. Front Microbiol 3:323.


[47] Masuda T*. Non-Enzymatic Functions of Retroviral Integrase: The Next Targetfor Novel Anti-HIV Drug Development. Front Microbiol. 2, 210. 2011

[46] Takamori A, Hasegawa A*, Utsunomiya A, Maeda Y, Yamano Y, Masuda M, Shimizu Y, Tamai Y, Sasada A, Zeng N, Choi I, Uike N, Okamura J, Watanabe T, Masuda T, Kannagi M. Functional impairment of Tax-specific but not cytomegalovirus-specific CD8+ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers. Retrovirology. 8: 100. (PubMed)

[45] Kannagi M*, Hasegawa A, Kinpara S, Shimizu Y, Takamori A, Utsunomiya A. Double control systems for human T-cell leukemia virus type 1 by innate and acquired immunity. Cancer Sci., 102(4):670-6.

2010

[44] Ahmed N, Hayashi T, Hasegawa A, Furukawa H, Okamura N, Chida T, Masuda T, Kannagi M*. Suppression of human immunodeficiency virus type 1 replication in macrophages by commensal bacteria preferentially stimulating Toll-like receptor 4. J Gen Virol., 91(Pt 11):2804-13.

[43] Hayashi T, Nishitsuji H, Takamori A, Hasegawa A, Masuda T*, Kannagi M. DNA-dependent activator of IFN-regulatory factors enhances the transcription of HIV-1 through NF-κB. Microbes Infect., 12(12-13):937-47.

2009

[42] Nishitsuji H, Hayashi T, Takahashi T, Miyano M, Kannagi M, Masuda T*. Augmentation of reverse transcription by integrase through an interaction with host factor, SIP1/Gemin2 Is critical for HIV-1 infection. PLoS One.(PubMed)

[41] N.Takatsuka, A. Hasegawa, A. Takamori, Y. Shimizu, H. Kato, T. Ohashi, T. Amagasa, T. Masuda, M. Kannagi*. Induction of IL-10- and IFN-g-producing T-cell responses by autoreactive T-cells expressing human T-cell leukemia virus type I Tax. Int. Immunol., 21(9):1089-100.

[40] S. Obitsu, N. Ahmed, H. Nishitsuji, A. Hasegawa, K. Nakahama, I. Morita, K. Nishigaki, T. Hayashi, T. Masuda, M. Kannagi*. Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. Arch. Virol., 154(9):1457-64.

[39] S. Kinpara, A. Hasegawa, A. Utsunomiya, H. Nishitsuji, H. Furukawa, T. Masuda, and M. Kannagi*. Stromal cell-mediated suppression of human T-cell leukemia virus type-1 expression in vitro and in vivo through type-I interferon. J Virol. 83: 5101-5108.(PubMed)

[38] Y. Shimizu, A. Takamori, A. Utsunomiya, M. Kurimura, Y.Yamano, M. Hishizawa, A. Hasegawa, F. Kondo, K. Kurihara, N. Harashima, T. Watanabe, J. Okamura, T. Masuda, and M. Kannagi*. Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer Sci., 100: 481-489. (PubMed)

2007

[37] M. Washiyma, K. Nishigaki, N. Ahmed, S. Kinpara, Y. Ishii, N. Kanzawa, T. Masuda, and M. Kannagi*. IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines. FEBS Letters, 581: 5207-5212. (PubMed)

[36] Mari Kannagi*. Immunologic control of HTLV-I and Adult T-cell Leukemia. Int. J. Hematol. 86: 113-117. (PubMed)

2006

[35] Kanzawa N, Nishigaki K, Hayashi T, Ishii Y, Furukawa S, Niiro A, Yasui F, Kohara M, Morita K, Matsushima K, Le MQ, Masuda T, Kannagi M*. Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-kappaB activation. FEBS Lett., 580(30):6807-12. (PubMed)

[34] Nishitsuji H, Kohara M, Kannagi M, Masuda T*. Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J Virol., 80(15):7658-66. (PubMed)

[33] Komori K, Hasegawa A, Kurihara K, Honda T, Yokozeki H, Masuda T, Kannagi M*. Reduction of human T-cell leukemia virus type 1 (HTLV-1) proviral loads in rats orally infected with HTLV-1 by reimmunization with HTLV-1-infected cells. J Virol., 80(15):7375-81. (PubMed)

[32] Hamamoto S, Nishitsuji H, Amagasa T, Kannagi M, Masuda T*. Identification of a novel human immunodeficiency virus type 1 integrase interactor, Gemin2, that facilitates efficient viral cDNA synthesis in vivo. J Virol., 80(12):5670-7. (PubMed)

[31] Kurihara K, Shimizu Y, Takamori A, Harashima N, Noji M, Masuda T, Utsunomiya A, Okamura J, Kannagi M*. Human T-cell leukemia virus type-I (HTLV-I)-specific T-cell responses detected using three-divided glutathione-S-transferase (GST)-Tax fusion proteins. J Immunol Methods., 313(1-2):61-73. (PubMed)

[30] Kubo M, Nishitsuji H, Kurihara K, Hayashi T, Masuda T, Kannagi M*. Suppression of human immunodeficiency virus type 1 replication by arginine deiminase of Mycoplasma arginini. J Gen Virol., 87(Pt 6):1589-93. (PubMed)

2005

[29] Harashima N, Tanosaki R, Shimizu Y, Kurihara K, Masuda T, Okamura J, Kannagi M. Identification of two new HLA-A*1101-restricted tax epitopes recognized by cytotoxic T lymphocytes in an adult T-cell leukemia patient after hematopoietic stem cell transplantation. J Virol., 79(15):10088-92.2005. (PubMed)

[28] Kannagi M, Harashima N, Kurihara K, Ohashi T, Utsunomiya A, Tanosaki R, Masuda M, Tomonaga M, Okamura J. Tumor immunity against adult T-cell leukemia. Cancer Sci., 96(5):249-55.2005. (PubMed)

[27] Kurihara K, Harashima N, Hanabuchi S, Masuda M, Utsunomiya A, Tanosaki R, Tomonaga M, Ohashi T, Hasegawa A, Masuda T, Okamura J, Tanaka Y, Kannagi M. Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer., 114(2):257-67.2005. (PubMed)

2004

[26] Ikeda T, Nishitsuji H, Zhou X, Nara N, Ohashi T, Kannagi M, Masuda T. Evaluation of the functional involvement of human immunodeficiency virus type 1 integrase in nuclear import of viral cDNA during acute infection. J Virol., 78(21):11563-73.2004.(PubMed)

[25] Emori Y, Ikeda T, Ohashi T, Masuda T, Kurimoto T, Takei M, Kannagi M. Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virol., 85(Pt 9):2603-13, 2004.(PubMed)

[24] Zhou X, Kubo M, Nishitsuji H, Kurihara K, Ikeda T, Ohashi T, Azuma M, Masuda T, Kannagi M. Inducible-costimulator-mediated suppression of human immunodeficiency virus type 1 replication in CD4+ T lymphocytes. Virology., 325(2):252-63, 2004. (PubMed)

[23] Kannagi M, Ohashi T, Harashima N, Hanabuchi S, Hasegawa A. Immunological risks of adult T-cell leukemia at primary HTLV-I infection. Trends Microbiol., 12(7):346-52, 2004. (PubMed)

[22] Kannagi M, Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Masuda M. Adult T-cell leukemia: future prophylaxis and immunotherapy. Expert Rev Anticancer Ther., 4(3):369-76, 2004. (PubMed)

[21] Nomura M, Ohashi T, Nishikawa K, Nishitsuji H, Kurihara K, Hasegawa A, Furuta RA, Fujisawa J, Tanaka Y, Hanabuchi S, Harashima N, Masuda T, Kannagi M. Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model. J Virol., 78(8):3827-36, 2004. (PubMed)

[20] Nishitsuji H, Ikeda T, Miyoshi H, Ohashi T, Kannagi M, Masuda T. Expression of small hairpin RNA by lentivirus-based vector confers efficient and stable gene-suppression of HIV-1 on human cells including primary non-dividing cells. Microbes Infect., 6(1):76-85, 2004. (PubMed)

[19] Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Hanabuchi S, Masuda M, Ohashi T, Fukui F, Hasegawa A, Masuda T, Takaue Y, Okamura J, Kannagi M. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res., ;64(1):391-9, 2004. (PubMed)

2003

[18] Liu H, Ohashi T, Masuda T, Zhou X, Kubo M, Kannagi M. Suppression of HIV-1 replication by HIV-1-irrelevant CD8+ cytotoxic T lymphocytes resulting in preservation of persistently HIV-1-infected cells in vitro. Viral Immunol., 16(3):381-93, 2003. (PubMed)

[17] Hasegawa A, Ohashi T, Hanabuchi S, Kato H, Takemura F, Masuda T, Kannagi M. Expansion of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Reservoir in Orally Infected Rats: Inverse Correlation with HTLV-1-Specific Cellular Immune Response. J Virol.,77:2956-63, 2003. (PubMed)

2002

[16] Ohashi T, Hanabuchi S, Suzuki R, Kato H, Masuda T, Kannagi M. Correlation of major histocompatibility complex class I downregulation with resistance of human T-cell leukemia virus type 1-infected T cells to cytotoxic T-lymphocyte killing in a rat model. J Virol.,76:7010-7019, 2002. (PubMed)

2001

[15] Hanabuchi S, Ohashi T, Koya Y, Kato H, Hasegawa A, Takemura F, Masuda T, Kannagi M. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity. J Natl Cancer Inst.,93:1775-83, 2001. (PubMed)

2000

[14] Kannagi M, Ohashi T, Hanabuchi S, Kato H, Koya Y, Hasegawa A, Masuda T, Yoshiki T. Immunological aspects of rat models of HTLV type 1-infected T lymphoproliferative disease. AIDS Res Hum Retroviruses,16:1737-40, 2000. (PubMed)

[13] T. Ohashi, S. Hanabuchi, H. Kato, H. Tateno, F. Takemura, T. Tsukahara, Y. Koya, A. Hasegawa, T. Masuda, and M. Kannagi. Prevention of Adult T cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with HTLV-I Tax-coding DNA vaccine. J Virol.,74:9610-9616, 2000. (PubMed)

[12] S. Hanabuchi, T. Ohashi, Y. Koya, H. Kato, F. Takemura, K. Hirokawa, T. Yoshiki, H. Yagita, K. Okumura, and M. Kannagi. Development of human T cell leukemia virus type I (HTLV-I)-transformed tumor in rats following suppression of T cell immunity by CD80 and CD86 blockade. J Virol.,74: 428-435, 2000. (PubMed)

[11] N. Tsurutani, M. Kubo, Y. Maeda, N. Yamamoto, M. Kannagi, and T. Masuda. Identification of critical amino acid residues in IN required for efficient proviral DNA formation at steps prior to integration in dividing and non-dividing cells. J Virol.,74: 4795-4806, 2000. (PubMed)

1999

[10] T. Ohashi, S. Hanabuchi, H. Kato, Y. Koya, F. Takemura, K. Hirokawa, T. Yoshiki, Y. Tanaka, M. Fujii, and M. Kannagi. Induction of ATL-like lymphproliferative disease and its inhibition by adoptive immunotherapy in T-cell deficient nude rats inoculated with syngenic HTLV-I-immortalized cells. J Virol.,73: 6031-6040, 1999. (PubMed)

[9] Y. Koya, T. Ohashi, H. Kato, S. Hanabuchi, T. Tsukahara, F. Takemura, K. Etoh, M. Matsuoka, M. Fujii, and M. Kannagi. Establishment of a seronegative HTLV-I-carrier state in rats inoculated with a syngeneic HTLV-I-immortalized T cell line preferentially expressing Tax. J Virol.,73: 6436-6443, 1999. (PubMed)

[8] T. Tsukahara, M. Kannagi, T. Ohashi, H. Kato, M. Arai, G. Nunez, Y. Iwanaga, N. Yamamoto, K. Ohtani, M. Nakamura, and M. Fujii. Induction of Bcl-xL expression by HTLV-I Tax through NF-kB in apoptosis-resistant T-cell transfectants with Tax. J Virol.,73: 7981-7987, 1999. (PubMed)

[7] T. Ohashi, M. Kubo, H. Kato, A. Iwamoto, H. Takahashi, M. Fujii, and M. Kannagi. Role of class I major histcompatibility complex-restricted and -unrestricted suppression of human immunodeficiency virus type 1 (HIV-1) replication by CD8+ T lymphocytes. J Gen Virol.,80: 209-216, 1999. (PubMed)

1998

[6] T. Ohashi, M. Arai, H. Kato, M. Kubo, M. Fujii, N. Yamamoto, A. Iwamoto, M. Kannagi. High SDF-1 expression in HIV-1 carriers does not correlate with CD8+ T cell-mediated suppression of viral replication. Virology, 244: 467-472, 1998. (PubMed)

[5] H. Kato, Y. Koya, T. Ohashi, S. Hanabuchi, F. Takemura, M. Fujii, H. Tsujimoto, A. Hasegawa, and M Kannagi. Oral administration of HTLV-I induces immune unresponsivenesswith persistent infection in adult rats. J Virol., 72. 7289-7293, 1998. (PubMed)

[4] M. Arai, T. Ohashi, T. Tsukahara, T. Murakami, T Hori, T. Uchiyama, N. Yamamoto, M. Kannagi, M. Fujii. Human T cell leukemia virus type 1 Tax protein induces the expression of lymphocyte chemoattractant SDF-1/PBSF. Virology, 241: 298-303, 1998. (PubMed)

1997

[3] Kubo M, Ohashi T., Fujii M., Oka S., Iwamoto S., Harada S., and Kannagi M. Abrogation ofin vitro suppression of HIV-1 replication mediated by CD8+ T lymphocytes of asymptomatic HIV-1 carrers by staphylococcal enterotoxin B and phorbol esters hrough induction of TNF-a. J Virol.,71: 7560-7566, 1997. (PubMed)

[2] Kishi S, Saijo S., Arai M., Karasawa S., Ueda S., Kannagi M., Iwakura Y., Fujii M., and Yonehara S. Resistance to Fas-mediated apoptosis of peripheral T cells in human T lymphocyte virus type I (HTLV-I) transgenic mice with autoimmune arthropathy. J Exp Med.,186: 57-64, 1997. (PubMed)

[1] Arai, M., Kannagi, M., Matsuoka, M., Sato, T., Yamamoto, N., Fujii, M. Expression of FAP-1(Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T-cell lines derived from human T-cell leukemia virus type 1 associated myelopathy/tropical spastic paraparesis. AIDS Res.Hum.Retroviruses, 14: 261-267, 1997. (PubMed)

東京医科歯科大学 ホームページへ戻る　 　　　 大学院医歯学総合研究科のページへ戻る

こ の ホームページのお問い合わせは にお願いいたします。